Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.

Dasanu CA, Alexandrescu DT, Dutcher J.

South Med J. 2007 Mar;100(3):328-30. Erratum in: South Med J. 2007 May;100(5):485.

PMID:
17396743
2.

[Cutaneous side effects of sorafenib and sunitinib].

Autier J, Mateus C, Wechsler J, Spatz A, Robert C.

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13. Review. French. No abstract available.

PMID:
18342102
3.

Sorafenib-induced erythema multiforme: three cases.

Namba M, Tsunemi Y, Kawashima M.

Eur J Dermatol. 2011 Nov-Dec;21(6):1015-6. doi: 10.1684/ejd.2011.1535. Review. No abstract available.

PMID:
21926043
4.

Sorafenib.

Hasskarl J.

Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5. Review.

PMID:
20072831
5.

Sorafenib in renal cell carcinoma.

Arranz JÁ, Climent MÁ, González-Larriba JL, León L, Maroto JP.

Crit Rev Oncol Hematol. 2011 Nov;80(2):314-22. doi: 10.1016/j.critrevonc.2011.01.008. Epub 2011 Mar 21. Review.

PMID:
21419641
6.

Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?

Degen A, Satzger I, Voelker B, Kapp A, Hauschild A, Gutzmer R.

Dermatology. 2010;221(3):193-6. doi: 10.1159/000317081. Review.

PMID:
20720388
7.

Toxicity of sorafenib: clinical and molecular aspects.

Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Francès C, Knebelmann B, Goldwasser F.

Expert Opin Drug Saf. 2010 Mar;9(2):275-87. doi: 10.1517/14740330903510608. Review.

PMID:
20078249
8.

Sorafenib.

Rini BI.

Expert Opin Pharmacother. 2006 Mar;7(4):453-61. Review.

PMID:
16503817
9.

[Sorafenib(Nexavar)].

Miyanaga N, Akaza H.

Gan To Kagaku Ryoho. 2009 Jun;36(6):1029-33. Review. Japanese.

PMID:
19542731
10.

Sorafenib (BAY 43-9006): review of clinical development.

Ng R, Chen EX.

Curr Clin Pharmacol. 2006 Sep;1(3):223-8. Review.

PMID:
18666747
11.

Sorafenib: a promising new targeted therapy for renal cell carcinoma.

Wood LS, Manchen B.

Clin J Oncol Nurs. 2007 Oct;11(5):649-56. Review.

PMID:
17962173
12.

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.

Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4. Review.

PMID:
19333228
13.

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.

Lipworth AD, Robert C, Zhu AX.

Oncology. 2009;77(5):257-71. doi: 10.1159/000258880. Epub 2009 Nov 16. Review.

PMID:
19923864
14.

Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.

Bracarda S, Ruggeri EM, Monti M, Merlano M, D'Angelo A, Ferraù F, Cortesi E, Santoro A; Sorafenib Working Group.

Crit Rev Oncol Hematol. 2012 Jun;82(3):378-86. doi: 10.1016/j.critrevonc.2011.08.005. Epub 2011 Sep 23. Review.

PMID:
21944842
15.

Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.

Kamada P, Dudek AZ.

Cancer Invest. 2010 Jun;28(5):501-4. doi: 10.3109/07357900903476794. Review.

PMID:
20014944
16.

[Hand-foot syndrome after administration of tyrosinkinase inhibitors].

Bednaríková D, Kocák I.

Klin Onkol. 2010;23(5):300-5. Review. Czech.

PMID:
21061680
17.

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

Porta C, Paglino C, Imarisio I, Bonomi L.

Clin Exp Med. 2007 Dec;7(4):127-34. doi: 10.1007/s10238-007-0145-8. Epub 2008 Jan 11. Review.

PMID:
18188524
18.

Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T.

Lancet Oncol. 2005 Jul;6(7):491-500. Review.

PMID:
15992698
19.

Targeting Raf-kinase: molecular rationales and translational issues.

Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P.

Ann Oncol. 2006 Jun;17 Suppl 7:vii124-7. Review.

PMID:
16760274
20.

Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.

Noel JK, Crean S, Claflin JE, Ranganathan G, Linz H, Lahn M.

Med Oncol. 2008;25(3):323-30. doi: 10.1007/s12032-008-9039-1. Epub 2008 Jan 19. Review.

PMID:
18204822

Supplemental Content

Support Center